Human iPSC-derived hepatocytes ReproHepato[™] for CYP assay & drug toxicity testing

Robert Annand, Rina Akahira, Kenichi Tamura, Mitsuru Inamura **ReproCELL Inc.**



Abstract & Objective Mass production of hepatocytes with high stability and low lot-to-lot variation

in.

Pharmaceutical candidate compounds require extended period of time and large amount of development costs before reaching the market. However, for various reasons, most of the candidates will be canceled in their development process. One major reason is hepatotoxicity. Recently, in the beginning of the drug screening process, simple and fast evaluation by so-called "Cell-based assay" has been given great importance in terms of A8 44 safety and cost reduction. Although human primary hepatocytes have been widely used for hepatotoxicity, the following problems still remain: lot-to-lot variation, commercial availability and unstable supply. Moreover, there is a great difficulty in executing long-term tests using hepatocytes from the identical donor.

Human-derived iPS cells are pluripotent stem cells with the ability of infinite proliferation Cultured and differentiation into various cells including hepatocytes. Therefore, iPS cells enable **IPS cells** unlimited production of hepatocytes possessing the same genetic back ground. Incubato Furthermore, it is possible to produce various donor-derived hepatocytes since humanderived iPS cells can be establish from varied race, sex and genetic back ground.

Materials & Methods

ReproHepato type I[™] kit (1 kit for 1 plate) (ReproCELL #RCESDH001)

- Cells 1 vial (8.25 million cells/vial)
- Thawing Medium 1 bottle
- Maintenance medium 1 bottle Assay Medium 1 bottle
- Supplements

CYP3A4 induction assav


- P450-Glo™ CYP3A4 Assay (Luciferin-PFBE) Cell-Based/Biochemical Assay, V8901 (Promega Corporation, Madison, WI, USA)
- Functional Drug Screening System FDSS/µCELL (Hamamatsu Photonics K.K., Shizuoka, Japan) Greiner tissue culture treated 96 well plates (Greiner ,
- Frickenhausen, German
- Hepatotoxicity assay
- Acetaminophen (Sigma #A7085) Amiodarone hydrochloride (Sigma #A8423)
- Cyclophosphamide monohydrate (Sigma #C0768)
- Diclofenac sodium salts (Sigma #D6899)
- Flutamide (Sigma #F9397) CellTiter-Glo™ Luminescent Cell Viability Assay (Promega
- #G7571)
- Cvtotoxicity Detection Kit^{PLUS} (LDH) (Roche #4744936) ARVOX3 (PerkinElmer Japan)

High Contents Analysis

Cell Insight NXT (Thermo Fisher)

Cyclophosphamide

 Drug Induced Liver Injury (DILI) Cartilage (Thermo Fisher



On the v-axis, the level of the Primary Hepatocytes was taken as

Acetam

Amk

Cyclophosphernide

Diciophenac

Flutamide

cell number

DNA content

glutathione (GSH)

notential (MMP)

mitochondrial membrane

100%.



Fig. 1. Stable supply of human iPS cell-derived hepatocyte applicable for toxicity screening

Upper: Primary hepatocytes, Lower: human iPS cell-derived hepatocyte (ReproHepato[™]) There is a limit in cell supply from the identical donor and lot-to-lot variation between each donors. On the other hand, human-derived iPS cells from the

overcome the problems mentioned above

Results : CYP Assav

Fig. 3. The changes of CYP3A4 activity of ReproHepato[™] in a dose-dependent manner, by rifampicin, dexamethasone, and ketoconazole as in the case of primary hepatocytes.

CYP3A4 activity of ReproHepato[™] is induced by rifampicin (A) and dexamethasone (B), and inhibited by ketoconazole (C). respectively, in a dose-dependent manner. ReproHepato™ show similar kinetics with primary hepatocytes in CYP3A4 assay.




Fig. 5. High content analysis by Cell insight NXT After exposure of five compounds possessing hepatotoxicity for 48 hours, photography and measurements of the dyed and agent-treated cells with Drug Induced Liver Injury (DILI) cartilage were done using cell imaging analyzer: Cell insight NXT. Concentration of the exposed compounds has been changed by 5-fold dilution to prepare six type of concentration. Here, 5 information such as mitochondrial membrane potential was extracted.

Conclusion

• In this study, we developed human iPS cellsderived hepatocytes (ReproHepato[™]), which can be used for CYP3A4 induction assays. Concentration-dependent toxicity has been confirmed by measurements of ATP and LDH. • By high content analysis, the following were simultaneously measured: cell number, intranuclear DNA, reduction in glutathione level, active oxygen and mitochondrial membrane potential.

Results : Drug Toxicity Testing ATP and LDH Assay Using ReproHepato[™] Acetaminophen Amiodarone Cyclophosphamide IC50, 2525 # M 1050, 0.5051 g M




Fig. 4. Measurements of Diciofenac ATP and LDH after 48hrs Drug Exposure to **ReproHepato[™]**

After exposure of five compounds possessing hepatotoxicity for 48 hours, ATP and LDH was measured. Concentration-dependent reduction of cell viability and toxicity was confirmed.

High Contents Analysis After Drug Exposure					
Cmax 0.1	.6 Cmex	0.8 Cmax	4 Cmax	20 Cmax	180 Cma
			-	•	

comparative to those of Primary Hepatocytes.

nuclear

nuclear

cyteplasm

nuclear,

cytoplasm

blue

blue

areen

red

identical donor are capable of infinite proliferation and are expected to